Botox® for idiopathic overactive bladder: Efficacy, duration and safety. Effectiveness of subsequent injection

Archives of Gynecology and Obstetrics

Volumn 286, Issue 4, 2012, Pages 923-929

  Granese, Roberta ^a   Adile, Giorgio ^b   Gugliotta, Giorgio ^b   Cucinella, Gaspare ^c   Saitta, Salvatore ^d   Adile, Biagio ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Hospital Villa Sofia   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Botox; Botulinum toxin type A; Idiopathic detrusor overactivity; Idiopathic overactive bladder; Urge incontinence

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; NOCTURIA; OVERACTIVE BLADDER; PHYSICAL EXAMINATION; POSTVOID RESIDUAL URINE VOLUME; PROSPECTIVE STUDY; QUALITY OF LIFE; RELAPSE; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; URINARY URGENCY; URINE CULTURE; URODYNAMICS; AGED; CLINICAL TRIAL; CYSTOSCOPY; INTRAMUSCULAR DRUG ADMINISTRATION; REOPERATION; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; CYSTOSCOPY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; PROSPECTIVE STUDIES; REOPERATION; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 84873480199     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2349-8     Document Type: Article

References (28)

1. van Ermengem E (1979) Classics in infectious diseases: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1:701-719
2. Sahai A, Dowson C, Khan MS et al (2009) Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 103:1509-1515
3. O'Brien CF (2002) Treatment of spasticity with botulinum toxin. Clin J Pain 18:S182-S190 (Review)
4. Stöhrer M, Wolff A, Kramer G et al (2007) Seven years of botulinum toxin type A in the treatment of neurogenic detrusor hyperactivity. Urologe A 46:1211-1218
5. Schmid DM, Roy S, Sulser T (2008) Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 1:7-10
6. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644-650 (Review)
7. Mohanty NK, Nayak RL, Alam M (2008) Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: single center experience. Indian J Urol 24:182-185
8. de Groat WC (2004) The urothelium in overactive bladder: passive bystander or active participant? Urology 64:7-11 (Review)
9. Chopra B, Barrick SR, Meyers S et al (2005) Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 562:859-871
10. De Sèze M, Ruffion A, Haab F et al (2008) Patient follow-up after botulinum toxin intradetrusor injection: proposal for management in neurogenic patients. Ann Readapt Med Phys 51:315-321
11. Abrams P, Cardozo L, Fall M et al (2002) Standardisation Subcommittee of the International Continence Society: the standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178
12. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP (1996) Quality of life of persons with urinary incontinence: development of a new measure. Urology 147:67-71 (Discussion 71-72)
13. Gamé X, Mouracade P, Chartier-Kastler E et al (2009) Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 5:156-164
14. Brubaker L, Richter HE, Visco A et al (2008) Pelvic floor disorders network: refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180:217-222
15. Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ (2009) Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 113:1046-1051
16. Mehnert U, Schurch B (2009) Botulinum toxin in nonneurogenic bladder dysfunction. Urologe A 48:233-244
17. Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245-1253
18. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172:240-243
19. Kessler TM, Khan S, Panicker JN et al (2010) In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results. Eur Urol 57:879-883
20. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692-697
21. Reitz A, Stöhrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510-515
22. Grosse J, Kramer G, Stöhrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653-659
23. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177-185
24. Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ (2008) Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 54:181-187
25. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528-535
26. Schurch B, de Sèze M, Denys P, Botox Detrusor Hyperreflexia Study Team et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196-200
27. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850-858
28. White WM, Pickens RB, Doggweiler R, Klein FA (2008) Shortterm efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 180:2522-2526